shares in zur rose group ag traded sharply higher after the company said it was expecting to break even on a key earnings metric one year earlier than previously announced despite a widened firsthalf net loss the swiss online pharmacy said on thursday that it expects to break even on the basis of adjusted earnings before interest taxes depreciation and amortization in 2023 a year ahead of its previouslystated goal that is the most positive news from the reporting period suggesting that the operating capital requirement is covered by current liquidity and zur rose doesnt need additional cash baader helvea analyst volker bosse said in a research note citi analysts however said in a research note that the company is caught in a catch22 and risks its competitive positioning with costsavings measures citi said zur roses lowered 2022 revenue forecast to a midsingle digit decline implies a decline in the highsingle to lowdouble digit range in the second half in citis view the only positive scenario for the company would be a faster online prescription rollout though the chances of that are low the companys firsthalf net loss widened to 861 million swiss francs 905 million from a chf77 million loss in the same period a year earlier revenue fell 34 to chf9639 million adjusted ebitda loss was chf492 million compared with chf429 million it said